ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Last year was an especially good year for U.S. initial public offerings of venture-capital-backed biotechnology firms. Biotech firms made up more than half of the year’s venture-backed IPOs, which is more than the previous five years combined, said John S. Taylor, head of research at the National Venture Capital Association. Overall, 2013 was also the best year since 2007 for venture-backed IPOs. A total of 82 start-up firms went public last year, according to NVCA and business information gatherer Thomson Reuters, up from 49 in 2012. A bulging pipeline of companies still awaits favorable market conditions, Taylor adds, and so NVCA is hopeful the upward trend will continue.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X